Skip to main content

Angioimmunoblastic T-Cell Lymphoma Clinical Trials

Review the angioimmunoblastic t-cell lymphoma clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 30

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients with Peripheral T-cell Lymphoma who Achieved a Complete Response at the End of the Initial Chemotherapy
Status: Active
Location: 137 locations
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Status: Active
Location: 83 locations
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Status: Active
Location: 20 locations
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Status: Active
Location: 22 locations
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Status: Active
Location: 11 locations
Ruxolitinib and Duvelisib for the Treatment of Relapsed or Refractory T- or NK-Cell Lymphoma
Status: Active
Location: 9 locations
Enasidenib with or without Rituximab for the Treatment of Relapsed and Refractory IDH2-Mutant Angioimmunoblastic T-cell Lymphoma
Status: Active
Location: 7 locations
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients with CD30-Positive Peripheral T-cell Lymphoma
Status: Active
Location: 5 locations
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Status: Active
Location: 7 locations
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Status: Active
Location: 4 locations
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Status: Active
Location: 3 locations
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
Status: Active
Location: 3 locations
CD5.CAR/28 T Cells, Cyclophosphamide, and Fludarabine in Treating Participants with Recurrent T-Cell Malignancies Expressing the CD5 Antigen
Status: Active
Location: 3 locations
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
Status: Active
Location: 3 locations
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
Status: Active
Location: 2 locations
Golidocitinib with or without Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone for the Treatment of Peripheral T-cell Lymphoma, GOLDEN Trial
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Chemotherapy with or without Total Body Irradiation before Stem Cell Transplant in Treating Patients with Hodgkin or Non-Hodgkin Lymphoma
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Ruxolitinib in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphomas
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Duvelisib and Venetoclax for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
iC9 CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells and Lymphodepleting Chemotherapy for the Treatment of Relapsed or Refractory T-cell Leukemia or Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Immune System Cells for the Treatment of Relapse or Refractory Hematological Cancers
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Ruxolitinib in Combination with CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
A Vaccine (VSV-hIFNβ-NIS) with or without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
Status: Active
Location: See ClinicalTrials.gov